Prime Medicine said Friday it successfully used a new, ultra-versatile form of genetic surgery called prime editing to edit liver cells in monkeys.
The results, presented at the European Society of Gene & Cell Therapy meeting in Brussels, are a major step for a technology that could transform treatment of numerous diseases.
“I think the big celebration here is we’re showing, in primates, for the company, that we have a delivery system that is working and is safe,” said Jeremy Duffield, Prime’s chief scientific officer.